Write your message
Volume 7, Issue 5 (September - October 2022)                   J Obstet Gynecol Cancer Res 2022, 7(5): 405-413 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pouryasin M, Mousavi A, Pakravesh J, Zare Kamel D, Nooriardabili S, Khodadad S, et al . The Prevalence of HPV and non-HPV STIs Among Iranian Women and Assessment of the HPV/non-HPV STIs Co-infection on Cervical Cell Changes. J Obstet Gynecol Cancer Res 2022; 7 (5) :405-413
URL: http://jogcr.com/article-1-502-en.html
1- Department of Molecular Diagnosis, Armin Pathobiology and Genetics Laboratory, Tehran, Iran
2- Department of Gynecology-Oncology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran , azamsadat_mousavi@yahoo.com
3- Department of IVF, Aban Hospital, Tehran, Iran
4- Department of Obstetrics and Gynecology, Atieh Hospital, Tehran, Iran
5- Department of Gynecology-Oncology, Erfan Hospital, Tehran, Iran
6- Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran
7- Department of Pathology, Armin Pathobiology and Genetics Laboratory, Tehran, Iran
Abstract:   (379 Views)

Background & Objective: Persistent infection with some types of Human papillomavirus (HPV), which are high-risk genotypes, can lead the patients toward cervical cancer and, finally, death. Recent studies showed HPV co-infection with non-HPV sexually transmitted infections (non-HPV STIs) could increase the persistency rate of HPV infections. This study aimed to estimate the prevalence of STIs and assess the association of HPV/non-HPV STIs co-infection on cervical cell changes based on cytological findings.
Materials & Methods: In this cross-sectional study, in addition to the routine cervical screening, including HPV testing and cytological assessment, non-HPV STI testing was performed on 1065 Iranian women. To assess the HPV and non-HPV STIs, commercial kits were used.
Results: 964 (90.5%) women had normal cytology (NILM) results. The overall prevalence of HPV and non-HPV STIs were 39.1% and 68.5%, respectively. HPV-53 (6.5%), -16 (6.1%) and -31 (5.5%) were found as the most prevalent genotypes. Ureaplasma Parvum (UP) (42.7%), Group B Streptococcus (GBS) (23.7%), Candida Species (CS) (23.6%), Ureaplasma Urealyticum (UU) (9.6%), and Mycoplasma Hominis (MH) (7.1%) were found as the most prevalent non-HPV STIs. The co-infection of HPV with GBS played an important role in developing the cervical lesion (P<0.05).
Conclusion: In the present study, the STIs, including HPV, UP, GBS, CS, UU, and MH, were prevalent among the study participant, and it was found that the HPV/GBS co-infection played a significant role in the development of LSIL or worse cytological grades. To clarify this issue, further studies will be conducted.

Full-Text [PDF 873 kb]   (179 Downloads) |   |   Full-Text (HTML)  (139 Views)  
Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2021/09/21 | Accepted: 2021/12/25 | Published: 2022/07/7

1. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9(6):347-56. [DOI:10.1016/S1473-3099(09)70108-2]
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F [DOI:10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F]
3. Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203. [DOI:10.1016/S2214-109X(19)30482-6]
4. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069. [DOI:10.1002/14651858.CD009069.pub3] [PMID] [PMCID]
5. Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res. 2017;179:168-82. [DOI:10.1016/j.trsl.2016.07.004] [PMID] [PMCID]
6. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2):260-5. [DOI:10.1016/j.virol.2008.11.046] [PMID]
7. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res. 2002;89(2):191-9. [DOI:10.1016/S0168-1702(02)00188-0]
8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological Agents. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100B.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK304348/.
9. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev. 2001;10(10):1021-7.
10. Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr. 2003(31):29-34. [DOI:10.1093/oxfordjournals.jncimonographs.a003478] [PMID]
11. Mousavi A-S, Akhavan S, Sabzi shahrbabaki F, Izadi-mood N, Yarandi F, Ghazimoghadam M, et al. Assessment of the Diagnostic Value of High-Risk HPV Molecular-based Methods for Triage of Iranian Women with Abnormal Cytological Findings of ASC-US and LSIL. J Obstet Gynecol Cancer Res. 2022;7(3):151-7. [DOI:10.30699/jogcr.7.3.151]
12. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-9. [DOI:10.1016/S1473-3099(07)70158-5]
13. Yousefzadeh A, Mostafavizadeh SM, Jarollahi A, Raeisi M, Garshasbi M, Siavashvahabi Z, et al. Human papillomavirus (HPV) prevalence and types among women attending regular gynecological visit in Tehran, Iran. Clin Lab. 2014;60(2):267-73. [DOI:10.7754/Clin.Lab.2013.130221] [PMID]
14. Sohrabi A, Hajia M, Jamali F, Kharazi F. Is incidence of multiple HPV genotypes rising in genital infections? J Infect Public Health. 2017;10(6):730-3. [DOI:10.1016/j.jiph.2016.10.006] [PMID]
15. Hajia M, Sohrabi A. Possible Synergistic Interactions Among Multiple HPV Genotypes in Women Suffering from Genital Neoplasia. Asian Pac J Cancer Prev. 2018;19(3):785-9.
16. Pouryasin M, Sharafi H, Mousavi AS, Khodadad S, Marjani M, Jamshidi F, et al. Distribution of Human Papillomavirus Genotypes in Liquid-based Samples; Abundance of HPV-53 in Tehran, Iran. Iran J Public Health. 2014;43(8):1159-60.
17. Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infect Agent Cancer. 2018;13:6. [DOI:10.1186/s13027-018-0178-5] [PMID] [PMCID]
18. Mousavi AS, Pouryasin A, Yarandi F, Pirzadeh L, Alipour A, Khodadad S, et al. Assessment of Cervical Cancer Molecular-Based Screening Tools; HPV-DNA Detection versus E6/E7 mRNA Testing; First Report of a Prospective Cohort Study among Iranian Women. Iran J Public Health. 2020;49(9):1734-42. [DOI:10.18502/ijph.v49i9.4093] [PMID] [PMCID]
19. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One. 2015;10(12):e0143304. [DOI:10.1371/journal.pone.0143304] [PMID] [PMCID]
20. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One. 2015;10(1):e114989. [DOI:10.1371/journal.pone.0114989] [PMID] [PMCID]
21. Kim Y, Kim J, Lee KA. Prevalence of sexually transmitted infections among healthy Korean women: implications of multiplex PCR pathogen detection on antibiotic therapy. J Infect Chemother. 2014;20(1):74-6. [DOI:10.1016/j.jiac.2013.08.005] [PMID]
22. Magana-Contreras M, Contreras-Paredes A, Chavez-Blanco A, Lizano M, De la Cruz-Hernandez Y, De la Cruz-Hernandez E. Prevalence of sexually transmitted pathogens associated with HPV infection in cervical samples in a Mexican population. J Med Virol. 2015;87(12):2098-105. [DOI:10.1002/jmv.24278] [PMID]
23. Alotaibi HJ, Almajhdi FN, Alsaleh AN, Obeid DA, Khayat HH, Al-Muammer TA, et al. association of sexually transmitted infections and human papillomavirus co-infection with abnormal cervical cytology among women in Saudi Arabia. Saudi J Biol Sci. 2020;27(6):1587-95. [DOI:10.1016/j.sjbs.2020.03.021] [PMID] [PMCID]
24. Kim HS, Kim TJ, Lee IH, Hong SR. Associations between sexually transmitted infections, high-risk human papillomavirus infection, and abnormal cervical Pap smear results in OB/GYN outpatients. J Gynecol Oncol. 2016;27(5):e49. [DOI:10.3802/jgo.2016.27.e49] [PMID] [PMCID]
25. Zhang D, Li T, Chen L, Zhang X, Zhao G, Liu Z. Epidemiological investigation of the relationship between common lower genital tract infections and high-risk human papillomavirus infections among women in Beijing, China. PLoS One. 2017;12(5):e0178033. [DOI:10.1371/journal.pone.0178033] [PMID] [PMCID]
26. Parthenis C, Panagopoulos P, Margari N, Kottaridi C, Spathis A, Pouliakis A, et al. The association between sexually transmitted infections, human papillomavirus, and cervical cytology abnormalities among women in Greece. Int J Infect Dis. 2018;73:72-7. [DOI:10.1016/j.ijid.2018.06.001] [PMID]
27. Zheng MY, Zhao HL, Di JP, Lin G, Lin Y, Lin X, et al. [association of human papillomavirus infection with other microbial pathogens in gynecology]. Zhonghua Fu Chan Ke Za Zhi. 2010;45(6):424-8.
28. de Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira EC, Pereira MW, et al. Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res. 2016;6(6):1371-83.
29. Magalhaes PA, Miranda CA, Lima EG, Moizeis RN, de Lima DB, Cobucci RN, et al. Genital tract infection with Chlamydia trachomatis in women attended at a cervical cancer screening program in Northeastern from Brazil. Arch Gynecol Obstet. 2015;291(5):1095-102. [DOI:10.1007/s00404-014-3514-z] [PMID]
30. Biernat-Sudolska M, Szostek S, Rojek-Zakrzewska D, Kopec J, Zawilinska B. [May ureaplasmas in genital tract of HPV-positive women influence abnormal cytology of cervix?]. Przegl Epidemiol. 2008;62(2):447-52.
31. Ekiel AM, Friedek DA, Romanik MK, Jozwiak J, Martirosian G. Occurrence of Ureaplasma parvum and Ureaplasma urealyticum in women with cervical dysplasia in Katowice, Poland. J Korean Med Sci. 2009;24(6):1177-81. [DOI:10.3346/jkms.2009.24.6.1177] [PMID] [PMCID]
32. Lukic A, Canzio C, Patella A, Giovagnoli M, Cipriani P, Frega A, et al. Determination of cervicovaginal microorganisms in women with abnormal cervical cytology: the role of Ureaplasma urealyticum. Anticancer Res. 2006;26(6C):4843-9.
33. Zhang C, Liu Y, Gao W, Pan Y, Gao Y, Shen J, et al. The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia. Cancer Med. 2018;7(5):2172-9. [DOI:10.1002/cam4.1471] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.